|
|
|
|
|
|
|
|
|
|
the financing round of Refined Diagnostics has just started. Refined Diagnostics is a MedTech start-up in the field of high-precision laser systems for medical cancer diagnostics. Even before the official start of the round, more than EUR 1.3 million EUR had already been committed by business angels and co-investors. The HTGF, Apex Ventures and the NRW.Bank are already invested.
Refined Diagnostics generates significant sales in the millions. Partners include Bayer AG, Bruker, UC Davis and the Niels Bohr Institute. Thomas Merk (Ex-ROFIN CEO with M&A experience) accompanies the company as an active business angel.
Refined Diagnostics' technology is based on the Nobel Prize-winning Raman laser technology and provides precise tissue analyses within minutes – directly during ongoing operations. |
|
|
|
|
|
|
|
|
| INVESTMENT HIGHLIGHTS |
|
|
|
|
| • |
|
Nobel Prize-winning Raman technology: Molecular fingerprint for high-precision cancer diagnostics. |
|
|
| • |
|
Intraoperative histology in minutes: Significantly shortened diagnosis times enable earlier therapy decisions. |
|
|
| • |
|
Patent-protected laser platform: Technological moat with a scaling base for future AI modules. |
|
|
| • |
|
Clinically validated, shortly before market entry: CE launch planned from 2027. |
|
|
| • |
|
Recurring revenues: Combination of system sales, lease and service model. |
|
|
| • |
|
Renowned investors on board: HTGF, NRW.BANK, Apex Ventures, Papst Invest and others. |
|
|
| • |
|
Experienced deal support: Thomas Merk (Ex-ROFIN CEO, Coherent EVP) accompanies as an active business angel. |
|
|
|
|
|
|
|
|
|
|
|
  |
|
|
|
|
|
| Find out more about the interdisciplinary team of physicists with multiple doctorates and MedTech experts in the pitch video, who combine laser physics, imaging, regulation and market entry expertise and thus clearly position Refined Diagnostics for scaling in the clinical environment. |
|
| WATCH NOW→ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Companisto GmbH |
|
Köpenicker Str. 154, 10997 Berlin
Managing Director: Tamo Zwinge, LL. M. and David Rhotert
Amtsgericht: Berlin Charlottenburg HRB 132811 B
VAT-ID: DE 276 014 929
Phone: +49 30 330 837 49
Email: service@companisto.com |
|
|
|
|
|
|
|
|
| You receive this newsletter because you have subscribed to it. You can unsubscribe at any time via the unsubscribe link. |
|
| The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity. |
|
|
|
|
|
|
